1. A stress-free strategy to correct point mutations in patient iPS cells
- Author
-
Jingli Cai, Elizabeth Kropf, Lorraine Iacovitti, and Ya-Ming Hou
- Subjects
0301 basic medicine ,QH301-705.5 ,Induced Pluripotent Stem Cells ,Biology ,Article ,03 medical and health sciences ,0302 clinical medicine ,CRISPR ,Humans ,Clustered Regularly Interspaced Short Palindromic Repeats ,Biology (General) ,Induced pluripotent stem cell ,Homologous Recombination ,Gene ,Genetics ,Point mutation ,Intron ,Gene targeting ,Cell Biology ,General Medicine ,Transfection ,Isogenic iPS cells ,Clone Cells ,030104 developmental biology ,Mutation ,CRISPR-Cas Systems ,CRISPR-Cas9 ,Homologous recombination ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
When studying patient specific induced pluripotent stem cells (iPS cells) as a disease model, the ideal control is an isogenic line that has corrected the point mutation, instead of iPS cells from siblings or other healthy subjects. However, repairing a point mutation in iPS cells even with the newly developed CRISPR-Cas9 technique remains difficult and time-consuming. Here we report a strategy that makes the Cas9 "knock-in" methodology both hassle-free and error-free. Instead of selecting a Cas9 recognition site close to the point mutation, we chose a site located in the nearest intron. We constructed a donor template with the fragment containing the corrected point mutation as one of the homologous recombination arms flanking a PGK-PuroR cassette. After selection with puromycin, positive clones were identified and further transfected with a CRE vector to remove the PGK-PuroR cassette. Using this methodology, we successfully repaired the point mutation G2019S of the LRRK2 gene in a Parkinson Disease (PD) patient iPS line and the point mutation R329H of the AARS1 gene in a Charcot-Marie-Tooth disease (CMT) patient iPS line. These isogenic iPS lines are ideal as a control in future studies.
- Published
- 2021